Kiniksa Pharmaceuticals, Ltd.
HealthcareNASDAQ:KNSA · NASDAQ Global Select
+$0.31 today
Vol 0.36M · Avg 0.68M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.4%
avg 6.0%
ROIC
8.2%
avg -49.9%
ROA
7.7%
avg -34.6%
Analysis
ROE is currently the strongest return metric at 10.4% versus its period average of 6.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sanj K. Patel | Chief Executive Officer & Chairman of the Board | $2.24M | — | 57 | $951,794.00 | 1.27% |
Ross Michael Moat | Executive VP, COO & Principal Operating Officer | $1.20M | — | 46 | $12,029.00 | 0.02% |
John F. Paolini | Executive Vice President & Chief Medical Officer | $1.13M | — | 61 | $86,720.00 | 0.12% |
Eben Tessari | Consultant | $1.13M | — | 44 | $23,130.00 | 0.03% |
Mark Ragosa | Executive VP & CFO | $1.08M | — | 52 | $17,457.00 | 0.02% |
Martina Struck | Senior VP & Chief Regulatory Officer | — | — | — | — | — |
Joseph Pirrello | Chief Business Officer | — | — | — | — | — |
Aaron Young | Chief Intellectual Property Officer | — | — | — | — | — |
Michael R. Megna | Senior Vice President & Chief Accounting Officer | — | — | 55 | $27,418.00 | 0.04% |
Jonathan Kirshenbaum | Investor Relations Officer | — | — | — | — | — |
Mei Jang | Senior VP & Chief Technical Officer | — | — | — | — | — |
Douglas Barry | Senior Vice President, Chief Legal Officer & Secretary | — | — | — | $2,026.00 | <0.01% |
Randy Perrin | Group Vice President & Global Medical Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
34
$45.94M
Net Sentiment
$45.94M
Net selling
Most Active
Patel Sanj K
7 transactions
1–10 of 34
Analysis
Insiders reported 0 buys worth $0.00 and 34 sells worth $45.94M over the last 12 months. That adds up to net selling of $45.94M. Patel Sanj K was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Apellis Pharmaceuticals, Inc.
APLS
$5.25B
Amicus Therapeutics, Inc.
FOLD
$4.55B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Veracyte, Inc.
NASDAQ:VCYT
$3.78B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Who manages KNSA?
Kiniksa Pharmaceuticals, Ltd. (KNSA) lists 13 active executives. The top listed executive is Sanj K. Patel, Chief Executive Officer & Chairman of the Board.
Are KNSA insiders buying or selling?
Recent insider activity shows net selling of $29.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.